https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / Expert Rev Anticancer Ther 2009 Feb;9(2):199-210
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / Expert Rev Anticancer Ther 2009 Feb;9(2):199-2102009-02-01 00:00:002009-02-01 00:00:00Hyperthermia as an adjunctive treatment for soft-tissue sarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / J. Immunol. 2009 Feb;182(3):1667-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / J. Immunol. 2009 Feb;182(3):1667-732009-02-01 00:00:002019-02-15 08:50:59Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / J. Immunol. 2009 Feb;182(3):1449-59
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / J. Immunol. 2009 Feb;182(3):1449-592009-02-01 00:00:002019-02-15 08:44:31Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / Curr Pharm Biotechnol 2009 Feb;10(2):166-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / Curr Pharm Biotechnol 2009 Feb;10(2):166-842009-02-01 00:00:002019-02-15 08:44:29Targeting the immune system in cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / J. Med. Virol. 2009 Feb;81(2):332-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / J. Med. Virol. 2009 Feb;81(2):332-92009-02-01 00:00:002019-02-15 08:37:34In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens
